Background Guidelines recommend continuation or initiation of guideline‐directed medical
therapy, including angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers …

Background The association between angiotensin-converting enzyme inhibitors (ACEI) and
angiotensin receptor blockers (ARB) doses on outcomes in patients with heart failure (HF) …

Aims Treatment with angiotensin converting enzyme inhibitor (ACEi)/angiotensin II receptors
blockers (ARBs) and beta‐blockers is frequently suboptimal at discharge in patients …

Background Heart failure is associated with high mortality and hospital readmissions. Beta‐
adrenergic blocking agents, angiotensin converting enzyme inhibitors (ACEIs), and …

Background Heart failure is the leading cause for 30-day all-cause readmission, the
reduction of which is a goal of the Affordable Care Act. There is a growing interest in …

Background: Existing clinical trial data do not address whether all angiotensin-converting-
enzyme (ACE) inhibitors are similarly beneficial in improving survival and reducing the rate …

In a retrospective, cohort design, clinical usage of digoxin, diuretic, and angiotensin-
converting enzyme (ACE) inhibitor was assessed in all patients readmitted over a 36-month …

This study was conducted to provide evidence of an association between angiotensin-
converting enzyme (ACE) inhibitor use and clinical outcomes among patients with …

Background Angiotensin-converting enzyme (ACE) inhibitors have been demonstrated to
reduce morbidity and mortality rates in patients with heart failure with left ventricular systolic …

Objectives To compare the efficacy and safety of angiotensin-converting enzyme inhibitors
(ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure. Patients …